1. Haggar F.A., Boushey R.P. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009 Nov; 22(4): 191-7. https://doi.org/10.1055/s-0029-1242458.
2. Birgisson H., Wallin U., Holmberg L., Glimelius B. Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. BMC Cancer. 2011 Oct 11; 11: 438. https://doi.org/10.1186/1471-2407-11-438.
3. Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med. 2005; 352(5): 476-487. https://doi.org/10.1056/NEJMra040958.
4. Brenner H., Kloor M., Pox C.P. Colorectal cancer. Lancet. 2014 Apr 26; 383(9927): 1490-1502. https://doi.org/10.1016/S0140-6736(13)61649-9.
5. Nagelkerke A., Sweep F.C., Geurts-Moespot A., Bussink J., Span P.N. Therapeutic targeting of autophagy in cancer. Part I: molecular pathways controlling autophagy. Semin Cancer Biol. 2015 Apr; 31: 89-98. https://doi.org/10.1016/j.semcancer.2014.05.004.
6. Klionsky D.J. Look people, “Atg” is an abbreviation for “autophagyrelated.” That’s it. Autophagy. 2012 Sep; 8(9): 1281-2. https://doi.org/10.4161/auto.21812.
7. Gil J., Pesz K.A., Sąsiadek M.M. May autophagy be a novel biomarker and antitumor target in colorectal cancer? Biomark Med. 2016 Oct; 10(10): 1081-1094. https://doi.org/10.2217/bmm-2016-0083
8. Nagelkerke A., Bussink J., Geurts-Moespot A., Sweep F.C., Span P.N. Therapeutic targeting of autophagy in cancer. Part II: pharmacological modulation of treatment- induced autophagy. Semin Cancer Biol. 2015 Apr; 31: 99-105. https://doi.org/10.1016/j.semcancer.2014.06.001.
9. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., Mukherjee C., Shi Y., Gélinas C., Fan Y., Nelson D.A., Jin S., White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006; 10: 51-64.
10. Schmitz K.J., Ademi C., Bertram S., Schmid K.W., Baba H.A. Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World J Surg Oncol. 2016 Jul 22; 14(1): 189. https://doi.org/10.1186/s12957-016-0946-x.
11. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., Mukherjee C., Shi Y., Gélinas C., Fan Y., Nelson D.A., Jin S., White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006; 10(1): 51-64. https://doi.org/10.1016/j.ccr.2006.06.001.
12. Lee J., Giordano S., Zhang J. Autophagy, mitochondria and oxidative stress: cross- talk and redox signalling. Biochem J. 2012 Jan 15; 441(2): 523-40. https://doi.org/10.1042/BJ20111451.
13. White E.J., Martin V., Liu J.L., Klein S.R., Piya S., Gomez-Manzano C., Fueyo J., Jiang H. Autophagy regulation in cancer development and therapy. Am. J. Cancer Res. 2011; 11(3):362-372.
14. Li B.X., Li C.Y., Peng R.Q., Wu X.J., Wang H.Y., Wan D.S., Zhu X.F., Zhang X.S. The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. Autophagy. 2009; 5(3): 303-306.
15. Bambury R.M., Rosenberg J.E. Actionable mutations in muscleinvasive bladder cancer. Curr Opin Urol. 2013 Sep; 23(5): 472-8. https://doi.org/10.1097/MOU.0b013e328363a3cd.
16. Ng V.C., Johnson J.J., Cuellar S. Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer. J Oncol Pharm Pract. 2015 Dec; 21(6): 433-42. https://doi.org/10.1177/1078155214540732.
17. Rolfo C., Giovannetti E., Hong D.S., Bivona T., Raez L.E., Bronte G., Buffoni L., Reguart N., Santos E.S., Germonpre P., Taron M., Passiglia F., Van Meerbeeck J.P., Russo A., Peeters M., Gil-Bazo I., Pauwels P., Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8): 990-1004. https://doi.org/10.1016/j.ctrv.2014.05.009.
18. Loong H.H., Yeo W. Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma. Onco Targets Ther. 2014 Apr 16; 7: 575-85. https://doi.org/10.2147/OTT.S46019.
19. Li L., Liu D., Qiu Z-X., Zhao S., Zhang L., Li W-M. The Prognostic Role of m-TOR and P-mTOR for Survival in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE. 2015; 10(2): e0116771. https://doi.org/10.1371/journal.pone.0116771.
20. Zhou X., Tan M., Stone Hawthorne V., Klos K.S., Lan K.H., Yang Y., Yang W., Smith T.L., Shi D., Yu D. Activation of the Akt Mammalian Target of Rapamycin 4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clin Cancer Res. 2004; 10: 6779-6788. https://doi.org/10.1158/1078-0432.CCR-04-0112.
21. Zhou L., Huang Y., Li J., Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Medical Oncology. 2009; 27: 255-261. https://doi.org/10.1007/s12032-009-9201-4.
22. Xiao L., Wang Y.C., Li W.S., Du Y. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009 Dec 13; 28: 152. https://doi.org/10.1186/1756-9966-28-152.
23. Cho D.H., Jo Y.K., Kim S.C., Park I.J., Kim J.C. Down-regulated expression of ATG5 in colorectal cancer. AntiCancer Res. 2012; 32(9): 4091-4096.
24. Choi J.H., Cho Y.S., Ko Y.H., Hong S.U., Park J.H., Lee M.A. Absence of autophagy-related proteins expression is associated with poor prognosis in patients with colorectal adenocarcinoma. Gastroenterol Res Pract. 2014; 2014: 179586. https://doi.org/10.1155/2014/179586.
25. Giatromanolaki A., Koukourakis M.I., Harris A.L., Polychronidis A., Gatter K.C., Sivridis E. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in colorectal adenocarcinomas. J Clin Pathol. 2010 Oct; 63(10): 867-72. https://doi.org/10.1136/jcp.2010.079525.
26. Pattingre S., Espert L., Biard-Piechaczyk M., Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie. 2008; 90: 313-323. https://doi.org/10.1016/j.biochi.2007.08.014.
27. Laddha S.V., Ganesan S., Chan C.S., White E. Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res. 2014 Apr; 12(4): 485-90. https://doi.org/10.1158/1541-7786.MCR-13-0614.
28. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., Cerami E., Sander C., Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 Apr 2; 6(269): pl1. https://doi.org/10.1126/scisignal.2004088.
29. Kelley R.K., Wang G., Venook A.P. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw. 2011 Nov; 9(11): 1293-302.
30. Xia P., Wang J.J., Zhao B.B., Song C. The role of beclin-1 expression in patients with gastric cancer: a meta-analysis. Tumour Biol. 2013 Dec; 34(6): 3303-7. https://doi.org/10.1007/s13277-013-1049-8.
31. Huang L., Wang S., Li S.S., Yang X.M. Prognostic significance of Beclin-1 expression in laryngeal squamous cell carcinoma. Pathol Oncol Res. 2013 Oct; 19(4): 771-7. https://doi.org/10.1007/s12253-013-9642-0.
32. Lin H.X., Qiu H.J., Zeng F., Rao H.L., Yang G.F., Kung H.F., Zhu X.F., Zeng Y.X., Cai M.Y., Xie D. Decreased expression of Beclin 1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma. PLoS One. 2013; 8(4): e60516. https://doi.org/10.1371/journal.pone.0060516.
33. Miracco C., Cosci E., Oliveri G., Luzi P., Pacenti L., Monciatti I., Mannucci S., De Nisi M.C., Toscano M., Malagnino V., Falzarano S.M., Pirtoli L., Tosi P. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int. J. Oncol. 2007; 30(2): 429-436.
34. Liu L., Meng T., Wang Q.S., Jin H.Z., Sun Z.Q., Jin B., Fang F., Wang H.J. Association of Beclin-1 and microRNA-30a expression with the severity and treatment response of colorectal cancer. Genet Mol Res. 2016 Apr 7; 15(2). https://doi.org/10.4238/gmr.15027704.